Our results are consistent with a recent integrated study on HCC, which identified that approximately 25% of HCC patients belong to an “Immune class” characterized by enrichment of immune cell infiltration, immune checkpoint expression, and active IFNγ signaling [16], greatly resembling that of the most immunotherapy-responsive cancers [44–46]. This evidence concerns the gene IFNG and hepatocellular carcinoma.